Enasidenib resistance management

Enasidenib (Enasidenib) is a targeted therapy for patients with a specific type of acute myeloid leukemia (AML). It works differently than most cancer drugs, instead of killing leukemia cells, it converts them into normal blood cells. When cells become resistant to ensidipine, additional mutations that allow the cells to resist the drug occur in the normal copy of IDH2.

Drug resistance, when a tumor stops responding to targeted therapy, is a serious problem in cancer treatment. Some patients may develop resistance to ensidipine. If a patient develops resistance to ensidipine, we can try to find other possible treatment targets and select appropriate drugs for treatment. For some patients, increasing the dose of ensidipine may help overcome resistance. This approach requires close collaboration with a physician and is individualized to the patient's specific circumstances. Combining ensidipine with other therapeutic agents may be an effective strategy. For example, in combination with standard chemotherapy regimens or other targeted therapies to enhance the effectiveness of treatment.

Ensiidi plain investigational medicine is not currently on the market in the country, nor is it covered by medical insurance. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.